Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02606747
Other study ID # 11372013
Secondary ID
Status Recruiting
Phase N/A
First received April 9, 2015
Last updated November 16, 2015
Start date March 2015
Est. completion date June 2016

Study information

Verified date November 2015
Source Peking University
Contact Ye Wang, Ph. D
Phone +8613718946837
Email wangyesmile@gmail.com
Is FDA regulated No
Health authority China: Beijing Municipal Health Bureau
Study type Observational

Clinical Trial Summary

This study will evaluate the balance ability of DPN (diabetic peripheral neuropathy)patients, which will help us to understand the relationship between peripheral and central nervous system, in order to early diagnosis and prevent the fall in DPN patients.


Description:

DPN is one of the most common complications of diabetes. The clinical manifestation of DPN contains sensory reduction, pain, muscle wastage and so on. Sensory and motor nervous are one of the most important factors in balance control, the reduction of balance ability will result in high risk of fall.

Most studies about DPN are focus on peripheral nervous, however, the central nervous system may also be involved in DPN patients. In this study, force platform, proprioception test and fMRI will be used to evaluate balance ability, proprioception and the brain function information of DPN patients, which will help to understand the relationship between peripheral and central nervous system.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender Both
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria:

- diabetics

- normal cognitive ability

- walk normally

- normal vision

Exclusion Criteria:

- other nervous system disease, foot ulcer

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
China Peking University First Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Geheng Yuan

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Berg Balance Scale In Berg Balance Scale, 14-item scale designed to measure balance of the adult in a clinical setting, including sitting to standing, standing unsupported, sitting unsupported, standing to sitting, transfers, standing with eyes closed, standing with feet together, reaching forward with outstretched arm, retrieving object from floor, turning to look behind, turning 360 degrees, placing alternate foot on stool, standing with one foot in front and standing on one foot. For each item, a five-point scale ranging from 0-4 was recorded. "0" indicates the lowest level of function and "4" the highest level of function. Total Score = 56. through study completion, an average of 6 months; Berg Balance Scale assessment Yes
Primary Brain complexity and connectivity Brain complexity and connectivity was assessed by fMRI (functional magnetic resonance imaging).
For each patient, an 8 minutes resting state fMRI signal was recorded. Brain complexity and connectivity was calculated from fMRI signal. By using AAL (automated anatomical labeling) template, the brain was separated into 90 regions. The complexity of each brain region was calculated and range from 50 to 100. "50" indicates the lowest complexity and "100" indicates the highest complexity. The connectivity between each region was also calculated and range from 0 to 1. "0" indicates the weakest connectivity and "1" indicates the strongest connectivity.
The brain complexity and connectivity in both DPN group and diabetics without DPN group could help us to explore the brain differences between two groups.
through study completion, an average of 6 months; brain complexity and connectivity assessment Yes
Primary Timed up and go Timed up and go test was to assess the walk speed of patients. In timed up and go test, the patient sit on a standard armchair and used regular footwear. The patient walk to a line that is 3 meters away, turn around at the line, walk back to the chair, and sit down. The test ends when the patient's buttocks touch the seat. Patients were instructed to use a comfortable and safe walking speed. A stopwatch was used to time the test (in seconds). through study completion, an average of 6 months; timed up and go assessment Yes
Primary Foot sole tactile threshold The foot sole tactile threshold test was to assess the vibration sensation of patients. In foot sole tactile threshold test, the patient was instructed to stand on a pair of vibration insoles. The vibration amplitude was adjusted by experimenter until the patient cannot aware the vibration. The vibration threshold of each foot was recorded from 1 to 100. "1" indicates the weakest vibration and "100" indicates the strongest vibration. through study completion, an average of 6 months; foot sole tactile threshold assessment Yes
See also
  Status Clinical Trial Phase
Completed NCT04025320 - The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy N/A
Completed NCT02659007 - Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga Phase 1
Completed NCT01953757 - A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2) N/A
Completed NCT01707979 - NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes N/A
Completed NCT00608439 - Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy Phase 2
Completed NCT00576277 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain Phase 1/Phase 2
Completed NCT00830011 - Cognitive Behavioral Therapy for Painful Diabetic Neuropathy N/A
Completed NCT00235443 - A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy Phase 2/Phase 3
Completed NCT00931879 - Lovaza® and Microvascular Function in Type 2 Diabetes Phase 4
Completed NCT00190970 - The Effect of Ruboxistaurin on Small Fiber Function Phase 2
Completed NCT00101426 - Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Phase 3
Completed NCT00238550 - Study of CBME in the Relief of Painful Diabetic Neuropathy Phase 2
Completed NCT05573685 - Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training N/A
Recruiting NCT02341261 - Activity for Diabetic Polyneuropathy N/A
Completed NCT01822925 - Study of DA-9801 to Treat Diabetic Neuropathy Phase 2
Completed NCT01690962 - A Nutritional Intervention for Diabetic Neuropathy N/A
Terminated NCT00993018 - A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy Phase 2
Withdrawn NCT02315235 - The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy N/A
Completed NCT00496457 - Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy Phase 2
Completed NCT02068027 - Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy Phase 2